{"id":2955,"date":"2014-06-30T12:01:30","date_gmt":"2014-06-30T12:01:30","guid":{"rendered":"http:\/\/ncjolt.org\/?p=2955"},"modified":"2020-06-04T20:53:42","modified_gmt":"2020-06-04T20:53:42","slug":"mayo-myriad-and-the-future-of-innovation-in-molecular-diagnostics-and-personalized-medicine","status":"publish","type":"post","link":"https:\/\/journals.law.unc.edu\/ncjolt\/articles\/mayo-myriad-and-the-future-of-innovation-in-molecular-diagnostics-and-personalized-medicine\/","title":{"rendered":"Mayo, Myriad, and the Future of Innovation in Molecular Diagnostics and Personalized Medicine"},"content":{"rendered":"<p>Contrary to popular perception, the Supreme Court\u2019s recent decision in <em>Association for Molecular Pathology v. Myriad Genetics, Inc.<\/em>, finding certain patent claims reciting isolated genomic DNA molecules patent ineligible is likely to have a relatively minor impact on the patenting of diagnostics and personalized medicine. Method claims generally play a much more important role than isolated DNA claims in the patenting of innovations in this important technological sector, and the Court\u2019s earlier decision in <em>Mayo v. Prometheus Labs<\/em> that held claims directed towards non-genetic methods of personalized medicine to be patent ineligible will likely prove significantly more problematic in this regard. This article analyzes <em>Myriad<\/em> and <em>Mayo<\/em> and discusses their implications, concluding with a critique of <em>Ariosa Diagnostics v. Sequenom<\/em>, a district court decision applying <em>Mayo<\/em> to genetic diagnostic method claims in a manner that, if followed by other courts, could substantially threaten the availability of adequate patent protection for molecular diagnostics and personalized medicine.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Contrary to popular perception, the Supreme Court\u2019s recent decision in Association for Molecular Pathology v. Myriad Genetics, Inc., finding certain patent claims reciting isolated genomic DNA molecules patent ineligible is likely to have a relatively minor impact on the patenting of diagnostics and personalized medicine. Method claims generally play a much more important role than <a href=\"https:\/\/journals.law.unc.edu\/ncjolt\/articles\/mayo-myriad-and-the-future-of-innovation-in-molecular-diagnostics-and-personalized-medicine\/\" class=\"more-link\">&#8230;<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[5,57,61],"tags":[],"_links":{"self":[{"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/posts\/2955"}],"collection":[{"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/comments?post=2955"}],"version-history":[{"count":1,"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/posts\/2955\/revisions"}],"predecessor-version":[{"id":7461,"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/posts\/2955\/revisions\/7461"}],"wp:attachment":[{"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/media?parent=2955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/categories?post=2955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/tags?post=2955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}